Vor Bio is a pioneering biotechnology company dedicated to transforming the treatment of autoimmune diseases by addressing their root causes rather than merely managing symptoms. With a focus on advancing telitacicept, a dual BAFF/APRIL inhibitor, Vor aims to redefine the future of autoimmune care through innovative therapies that have shown promising results across various conditions, including myasthenia gravis, lupus, IgA nephropathy, and Sjögren’s syndrome. The company fosters a culture of belonging and collaboration, encouraging every team member to contribute to its mission of improving patient outcomes worldwide. Vor Bio is committed to supporting its employees with comprehensive benefits and opportunities for professional growth in a rapidly scaling environment.